Get our Newsletter
Sign up to receive the Pet Perspective, a monthly e-newsletter filled with videos and articles about pet health and other fun topics.
BluePearl – Overland Park will be participating in a funded clinical trial designed to evaluate the safety and preliminary anti-cancer activity of a novel, monoclonal antibody in dogs with measurable cancer. An estimated 20 client-owned dogs with melanoma or mast cell tumors will be enrolled. The antibody is administered IV by the study staff every 14 days for up to 10 treatments. No placebo is used in this trial. Visits will be required every 2 weeks for a total trial period of 140 days.
The trial is fully funded for the duration of the study (140 days), including the antibody and trial-related procedures.
Dogs with one of the following cancers may be enrolled if they meet the specific criteria for each cancer: